Dana-Farber Cancer Institute
Boston, MA
Accepting patients
DFV890
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
- NLRP3 Inhibitor
- Phase 1
- Has results
Accepting patients
ACCESS
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
- Allogeneic Stem Cell Transplant
- Pre-Transplant
- Phase 2
Accepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
PROMISE
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- High Risk
- Observational
- Observational Trial
Accepting patients
TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IRAK 4 Inhibitor
- Phase 1/2
- Has results
Accepting patients
BXCL701
A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2
- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Phase 1
Accepting patients
SL-401
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
AZD6738
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
- Kinase Inhibitor
- Phase 1
Accepting patients
ARC-T Cells Plus SPRX002
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
- CAR T Cell
- Phase 1
Accepting patients
IS-free Treg Stem Cell Transplant
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
- Allogeneic Stem Cell Transplant
- Phase 1